Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $26.03 and last traded at $26.54, with a volume of 86040 shares changing hands. The stock had previously closed at $27.71.
Wall Street Analyst Weigh In
AGIO has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $56.57.
View Our Latest Report on Agios Pharmaceuticals
Agios Pharmaceuticals Price Performance
The company's 50-day moving average is $31.70 and its two-hundred day moving average is $39.55. The firm has a market cap of $1.51 billion, a P/E ratio of 2.32 and a beta of 0.83.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $33,000. GF Fund Management CO. LTD. acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $39,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. Sterling Capital Management LLC increased its position in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 1,587 shares during the period. Finally, KBC Group NV increased its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the period.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
See Also
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
